Distinct expression profile of key molecules in crawling-type early gastric carcinoma

Ha Young Woo, Yoon Sung Bae, Jie Hyun Kim, Sang Kil Lee, Yong Chan Lee, Jae Ho Cheong, Sung Hoon Noh, Hyunki Kim

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Gastric “crawling-type” adenocarcinoma (CRA) is a tumor histologically characterized by irregularly fused glands with low-grade cellular atypia that tends to spread laterally in the mucosa. To date, the expression characteristics of the key molecules involved in CRA, including receptor tyrosine kinases (RTKs), mismatch repair (MMR) proteins, phosphatase and tensin homolog (PTEN), as well as the Epstein–Barr virus (EBV) status, have yet to be uncovered. Methods: We constructed tissue microarrays of 94 CRAs, 72 conventional-type differentiated adenocarcinomas (CDAs), and 71 intramucosal poorly cohesive adenocarcinomas (PCAs) from early gastric cancers to evaluate and compare the pathological and expression profiles of potential key molecules for molecular classification (EBV; four MMR proteins–MLH1, MSH2, PMS2, and MSH6; three RTKs–HER2, MET, and EGFR; PTEN; and p53). Results: None of the CRAs showed MMR deficiency (0.0 % vs. 5.6 %, CRA vs. CDA, p = 0.036), HER2 overexpression (0.0 % vs. 12.5 %, p = 0.001), or loss of PTEN expression (0.0 % vs. 9.7 %, p = 0.003). Moreover, MET overexpression (4.4 % vs. 19.4 %, p = 0.004), and a mutant p53 pattern (12.4 % vs. 62.5 %, p < 0.001) were significantly less common in CRAs than in CDAs. However, clinicopathological features and all the profile of the molecules of CRAs were close to those of the PCA group. Conclusions: CRA demonstrated unique clinicopathological characteristics and showed a distinct expression profile of key molecules, which was close to that of a null phenotype. These results support the classification of CRA as a distinct subgroup of gastric adenocarcinoma.

Original languageEnglish
Pages (from-to)612-619
Number of pages8
JournalGastric Cancer
Volume20
Issue number4
DOIs
Publication statusPublished - 2017 Jul 1

Fingerprint

Stomach
Adenocarcinoma
Carcinoma
DNA Mismatch Repair
Phosphoric Monoester Hydrolases
Viruses
Phosphoprotein Phosphatases
Receptor Protein-Tyrosine Kinases
Stomach Neoplasms
Mucous Membrane
Phenotype

All Science Journal Classification (ASJC) codes

  • Oncology
  • Gastroenterology
  • Cancer Research

Cite this

Woo, Ha Young ; Bae, Yoon Sung ; Kim, Jie Hyun ; Lee, Sang Kil ; Lee, Yong Chan ; Cheong, Jae Ho ; Noh, Sung Hoon ; Kim, Hyunki. / Distinct expression profile of key molecules in crawling-type early gastric carcinoma. In: Gastric Cancer. 2017 ; Vol. 20, No. 4. pp. 612-619.
@article{06d24977b07841088d0385e74f089541,
title = "Distinct expression profile of key molecules in crawling-type early gastric carcinoma",
abstract = "Background: Gastric “crawling-type” adenocarcinoma (CRA) is a tumor histologically characterized by irregularly fused glands with low-grade cellular atypia that tends to spread laterally in the mucosa. To date, the expression characteristics of the key molecules involved in CRA, including receptor tyrosine kinases (RTKs), mismatch repair (MMR) proteins, phosphatase and tensin homolog (PTEN), as well as the Epstein–Barr virus (EBV) status, have yet to be uncovered. Methods: We constructed tissue microarrays of 94 CRAs, 72 conventional-type differentiated adenocarcinomas (CDAs), and 71 intramucosal poorly cohesive adenocarcinomas (PCAs) from early gastric cancers to evaluate and compare the pathological and expression profiles of potential key molecules for molecular classification (EBV; four MMR proteins–MLH1, MSH2, PMS2, and MSH6; three RTKs–HER2, MET, and EGFR; PTEN; and p53). Results: None of the CRAs showed MMR deficiency (0.0 {\%} vs. 5.6 {\%}, CRA vs. CDA, p = 0.036), HER2 overexpression (0.0 {\%} vs. 12.5 {\%}, p = 0.001), or loss of PTEN expression (0.0 {\%} vs. 9.7 {\%}, p = 0.003). Moreover, MET overexpression (4.4 {\%} vs. 19.4 {\%}, p = 0.004), and a mutant p53 pattern (12.4 {\%} vs. 62.5 {\%}, p < 0.001) were significantly less common in CRAs than in CDAs. However, clinicopathological features and all the profile of the molecules of CRAs were close to those of the PCA group. Conclusions: CRA demonstrated unique clinicopathological characteristics and showed a distinct expression profile of key molecules, which was close to that of a null phenotype. These results support the classification of CRA as a distinct subgroup of gastric adenocarcinoma.",
author = "Woo, {Ha Young} and Bae, {Yoon Sung} and Kim, {Jie Hyun} and Lee, {Sang Kil} and Lee, {Yong Chan} and Cheong, {Jae Ho} and Noh, {Sung Hoon} and Hyunki Kim",
year = "2017",
month = "7",
day = "1",
doi = "10.1007/s10120-016-0652-y",
language = "English",
volume = "20",
pages = "612--619",
journal = "Gastric Cancer",
issn = "1436-3291",
publisher = "Springer Japan",
number = "4",

}

Distinct expression profile of key molecules in crawling-type early gastric carcinoma. / Woo, Ha Young; Bae, Yoon Sung; Kim, Jie Hyun; Lee, Sang Kil; Lee, Yong Chan; Cheong, Jae Ho; Noh, Sung Hoon; Kim, Hyunki.

In: Gastric Cancer, Vol. 20, No. 4, 01.07.2017, p. 612-619.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Distinct expression profile of key molecules in crawling-type early gastric carcinoma

AU - Woo, Ha Young

AU - Bae, Yoon Sung

AU - Kim, Jie Hyun

AU - Lee, Sang Kil

AU - Lee, Yong Chan

AU - Cheong, Jae Ho

AU - Noh, Sung Hoon

AU - Kim, Hyunki

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Background: Gastric “crawling-type” adenocarcinoma (CRA) is a tumor histologically characterized by irregularly fused glands with low-grade cellular atypia that tends to spread laterally in the mucosa. To date, the expression characteristics of the key molecules involved in CRA, including receptor tyrosine kinases (RTKs), mismatch repair (MMR) proteins, phosphatase and tensin homolog (PTEN), as well as the Epstein–Barr virus (EBV) status, have yet to be uncovered. Methods: We constructed tissue microarrays of 94 CRAs, 72 conventional-type differentiated adenocarcinomas (CDAs), and 71 intramucosal poorly cohesive adenocarcinomas (PCAs) from early gastric cancers to evaluate and compare the pathological and expression profiles of potential key molecules for molecular classification (EBV; four MMR proteins–MLH1, MSH2, PMS2, and MSH6; three RTKs–HER2, MET, and EGFR; PTEN; and p53). Results: None of the CRAs showed MMR deficiency (0.0 % vs. 5.6 %, CRA vs. CDA, p = 0.036), HER2 overexpression (0.0 % vs. 12.5 %, p = 0.001), or loss of PTEN expression (0.0 % vs. 9.7 %, p = 0.003). Moreover, MET overexpression (4.4 % vs. 19.4 %, p = 0.004), and a mutant p53 pattern (12.4 % vs. 62.5 %, p < 0.001) were significantly less common in CRAs than in CDAs. However, clinicopathological features and all the profile of the molecules of CRAs were close to those of the PCA group. Conclusions: CRA demonstrated unique clinicopathological characteristics and showed a distinct expression profile of key molecules, which was close to that of a null phenotype. These results support the classification of CRA as a distinct subgroup of gastric adenocarcinoma.

AB - Background: Gastric “crawling-type” adenocarcinoma (CRA) is a tumor histologically characterized by irregularly fused glands with low-grade cellular atypia that tends to spread laterally in the mucosa. To date, the expression characteristics of the key molecules involved in CRA, including receptor tyrosine kinases (RTKs), mismatch repair (MMR) proteins, phosphatase and tensin homolog (PTEN), as well as the Epstein–Barr virus (EBV) status, have yet to be uncovered. Methods: We constructed tissue microarrays of 94 CRAs, 72 conventional-type differentiated adenocarcinomas (CDAs), and 71 intramucosal poorly cohesive adenocarcinomas (PCAs) from early gastric cancers to evaluate and compare the pathological and expression profiles of potential key molecules for molecular classification (EBV; four MMR proteins–MLH1, MSH2, PMS2, and MSH6; three RTKs–HER2, MET, and EGFR; PTEN; and p53). Results: None of the CRAs showed MMR deficiency (0.0 % vs. 5.6 %, CRA vs. CDA, p = 0.036), HER2 overexpression (0.0 % vs. 12.5 %, p = 0.001), or loss of PTEN expression (0.0 % vs. 9.7 %, p = 0.003). Moreover, MET overexpression (4.4 % vs. 19.4 %, p = 0.004), and a mutant p53 pattern (12.4 % vs. 62.5 %, p < 0.001) were significantly less common in CRAs than in CDAs. However, clinicopathological features and all the profile of the molecules of CRAs were close to those of the PCA group. Conclusions: CRA demonstrated unique clinicopathological characteristics and showed a distinct expression profile of key molecules, which was close to that of a null phenotype. These results support the classification of CRA as a distinct subgroup of gastric adenocarcinoma.

UR - http://www.scopus.com/inward/record.url?scp=84991112552&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991112552&partnerID=8YFLogxK

U2 - 10.1007/s10120-016-0652-y

DO - 10.1007/s10120-016-0652-y

M3 - Article

C2 - 27734272

AN - SCOPUS:84991112552

VL - 20

SP - 612

EP - 619

JO - Gastric Cancer

JF - Gastric Cancer

SN - 1436-3291

IS - 4

ER -